St. Louis, MO – Phil Cotter, PhD, FACMG, FFSc (RCPA), Laboratory Director and Co-Founder of PacificDx, has been asked to present at the June AGT’s 42nd Annual Meeting speaking on The Pathway to FDA Approval for NGS Companion Diagnostics.
The presentation is described as follows –
“The FDA has prescribed a pathway for the co-approval of therapeutics and companion diagnostics. In recent years, a numberof molecular companion diagnostics have been FDA approved. Dr. Cotter will provide an overview of, and discusses the pathway to, FDA approval using an NGS based companion diagnostic in oncology as an example.”